Table 2.

Summary of the antitumor activity of SKLB-23bb against solid tumor xenografts

AdministrationToxicity
ModelGroupDose (mg/kg)ScheduleRouteMax body weight loss (%)DeathTumor inhibition rate (%)
hct116VehicleTIWp.o.4.90/7
SKLB-23bb12.5TIWp.o.4.20/751.28
SKLB-23bb25TIWp.o.3.80/760.37
SKLB-23bb50TIWp.o.5.40/766.05
A2780sVehicleTIWp.o.4.80/7
SKLB-23bb3TIWp.o.2.70/730.65
SKLB-23bb6TIWp.o.2.90/762.19
SKLB-23bb12.5TIWp.o.2.70/775.50
SKLB-23bb25TIWp.o.6.90/777.39
MCF-7VehicleTIWp.o.4.50/6
SKLB-23bb12.5TIWp.o.2.10/630.57
SKLB-23bb25TIWp.o.3.90/650.51
SKLB-23bb50TIWp.o.1.80/665.65
  • Abbreviation: BIW, twice a week; p.o., orally; TIW, thrice a week.